Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive
(firmenpresse) - NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- 11/11/14 -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax Incentive payment of $1.4M for the financial year ending 30 June 2014.
"The payment resulting from Australia''s R&D Tax Incentive program provides an important additional resource to innovate new advancements and explore additional applications for our proprietary technology platform, ReCell® Spray-On Skin®," commented Tim Rooney, Avita Medical''s Interim Chief Executive Officer.
Avita Medical () develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita''s patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient''s own skin. The Company''s lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.
Avita Medical Ltd.
Tim Rooney
Interim Chief Executive Officer/Chief Financial Officer
Phone: + 1 (818) 827-1695
Email:
Avita Medical Ltd.
Lou Panaccio
Chairman
Phone: +61 (0) 8 9474 7738
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2014 - 04:30 Uhr
Sprache: Deutsch
News-ID 1317185
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive
"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
